1. Home
  2. GRFS vs MDGL Comparison

GRFS vs MDGL Comparison

Compare GRFS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRFS
  • MDGL
  • Stock Information
  • Founded
  • GRFS 1940
  • MDGL 2011
  • Country
  • GRFS Spain
  • MDGL United States
  • Employees
  • GRFS N/A
  • MDGL N/A
  • Industry
  • GRFS Biotechnology: Pharmaceutical Preparations
  • MDGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRFS Health Care
  • MDGL Health Care
  • Exchange
  • GRFS Nasdaq
  • MDGL Nasdaq
  • Market Cap
  • GRFS 7.2B
  • MDGL 6.1B
  • IPO Year
  • GRFS 2006
  • MDGL N/A
  • Fundamental
  • Price
  • GRFS $10.13
  • MDGL $432.89
  • Analyst Decision
  • GRFS Hold
  • MDGL Strong Buy
  • Analyst Count
  • GRFS 1
  • MDGL 10
  • Target Price
  • GRFS $10.30
  • MDGL $463.78
  • AVG Volume (30 Days)
  • GRFS 794.7K
  • MDGL 402.0K
  • Earning Date
  • GRFS 01-01-0001
  • MDGL 10-30-2025
  • Dividend Yield
  • GRFS 1.41%
  • MDGL N/A
  • EPS Growth
  • GRFS 132.60
  • MDGL N/A
  • EPS
  • GRFS 0.53
  • MDGL N/A
  • Revenue
  • GRFS $8,744,226,659.00
  • MDGL $515,547,000.00
  • Revenue This Year
  • GRFS $6.00
  • MDGL $394.12
  • Revenue Next Year
  • GRFS $6.71
  • MDGL $57.74
  • P/E Ratio
  • GRFS $24.82
  • MDGL N/A
  • Revenue Growth
  • GRFS 9.32
  • MDGL 3421.98
  • 52 Week Low
  • GRFS $6.19
  • MDGL $200.63
  • 52 Week High
  • GRFS $11.14
  • MDGL $443.00
  • Technical
  • Relative Strength Index (RSI)
  • GRFS 52.17
  • MDGL 75.83
  • Support Level
  • GRFS $9.57
  • MDGL $422.02
  • Resistance Level
  • GRFS $9.99
  • MDGL $443.00
  • Average True Range (ATR)
  • GRFS 0.18
  • MDGL 16.41
  • MACD
  • GRFS -0.05
  • MDGL 0.56
  • Stochastic Oscillator
  • GRFS 51.85
  • MDGL 88.97

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Share on Social Networks: